DANAHER CORP /DE/ News
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, municipal, industrial, and natural resource applications. It also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. The company was founded in 1969 and is headquartered in Washington, the District of Columbia.
see moreDANAHER CORP /DE/ Market News
11d
Danaher Faces Masimo Fallout, Bioprocessing Gains!
- Danaher's recent week was shaped by lingering investor concern over the Masimo acquisition, modest stock weakness, and concrete signs of recovery in bioprocessing. China reimbursement pressures continue to weigh on diagnostics, while targeted product launches and digital pathology partnerships offer clear, near-term operational levers.
18d
Danaher Faces Slowing Diagnostics Demand, Stock Hit
Danaher (DHR) is showing early signs of pressure as recent industry reports point to weaker consumables demand across diagnostics and life sciences. While the company’s strategic Masimo acquisition positions it for longer-term growth in remote monitoring and software-enabled care, near-term recurring revenue softness and integration costs have heightened investor scrutiny.
25d
Danaher Buys Masimo: DHR Share Impact Analyzed Now
Danaher's announced acquisition of Masimo for $9.9B at $180 per share has stirred investor debate: Masimo jumped on the premium, while DHR slipped amid concerns about financing, leverage and integration. This article breaks down the deal specifics, near-term stock reaction, and the key metrics investors should monitor.
09 Mar at 04:28
Danaher $9.9B Masimo Buy Dampens DHR Shares Update
Danaher's confirmed $9.9 billion cash acquisition of Masimo at $180 per share (about a 38% premium) is the week's headline in diagnostics. Masimo rallied while Danaher shares fell roughly 7% as investors weigh deal financing, integration risks, and regulatory review. This article explains the transaction, near-term impacts on DHR, and what investors should monitor next.
02 Mar at 04:29
Danaher $9.9B Masimo Deal: EPS Upside, Risks Ahead
Danaher’s announced acquisition of Masimo for roughly $9.9 billion reshapes DHR’s diagnostics and monitoring exposure. The deal—cash at $180 per share—targets patient-monitoring technology and offers near-term EPS accretion and multi-year synergy potential, while integration execution and regulatory review pose the main risks.
23 Feb at 04:29
Danaher’s $10B Masimo Buy: $180 Deal Shakes DHR Up
Danaher announced a roughly $10 billion all-cash purchase of Masimo at $180 per share, a deal billed as near-term EPS accretive with meaningful cost and revenue synergies. The acquisition bolsters Danaher’s diagnostics and patient-monitoring capabilities; markets reacted with a sharp rise in Masimo shares and modest pressure on DHR as investors weigh integration and financing.
16 Feb at 04:28
Danaher Tops Q4; Diagnostics & Precision Push Now!
Danaher reported stronger-than-expected Q4 results, raised 2026 guidance range, and showed tangible momentum in diagnostics—driven by new-product launches, a stabilization in China, and a strategic tie-up with AstraZeneca—positioning DHR for durable growth across life-science instruments and molecular diagnostics.